Phio Pharmaceuticals is focused on developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYLTM) therapeutic platform. Immunotherapies harness our immune system to restore surveillance of tumors that evade detection – a potential curative medicine. INTASYLTM therapeutics can be used as a standalone treatment or in combination with other modalities.
Provided by Nasdaq.
Jan 11 - Jan 14, 2021H.C. WAINWRIGHT BIOCONNECT 2021 CONFERENCE
Dec 1 - Dec 4, 20203RD ANNUAL EVERCORE ISI HEALTHCONX CONFERENCE
Nov 9 - Nov 14, 2020SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 2020 ANNUAL MEETING